The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...
BALTIMORE, MD, December 3, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic ...